// App-Quantinova.ai

Su1928 : A PHASE 1/2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE INDUCTION OF CLINICAL RESPONSE AND REMISSION BY QBECO IN SUBJECTS WITH MODERATE TO SEVERE Crohn's DISEASE

Researchers

Presenter

  • Simon Sutcliffe

Principal Investigators

  • Jim Pankovich

  • Jenny M. Chen

  • Gillian Vandermeirsch

  • Darby Thompson

  • Richard N. Fedorak

  • Remo Panaccione

  • Jeffrey L. Axler

  • Brian Bressler

Medical Centers

  • Hepatology, University of Alberta, Edmonton, Alberta, Canada

  • Emmes Canada, Burnaby, British Columbia, Canada

  • Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada

  • GI Research Institute, Vancouver, British Columbia, Canada

  • Toronto Digestive Disease Associates Inc.

Locations

  • Canada

Companies

  • Qu Biologics Inc.

Study Components

Therapeutic Area

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • Unknown

Study Design

  • open label

  • randomized

  • double blind/blinded

  • adaptive

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved